Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Blood Advances|May 16, 2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinibFarrukh T Awan, Anna Schuh, Jennifer R Brown, et al.
Kidney International|February 5, 2015
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesChristoph Licht, Larry A Greenbaum, Petra Muus, et al.
Clinical Epigenetics|October 4, 2025
Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samplesBarrett Nuttall, Daniel L Karl, Kathleen Burke, et al.
Blood|June 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trialJohn F Seymour, John C Byrd, Paolo Ghia, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Blood Advances|April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-upRoger G Owen, Helen McCarthy, Shirley D'Sa, et al.
The Lancet. Oncology|December 17, 2017
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A Jones, Anthony R Mato, William G Wierda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jirí Mayer, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood Advances|March 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemiaRichard R Furman, William G Wierda, Piers Em Patten, et al.
Pageof 14